Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Lung Cancer. 2015 Sep 21;90(2):321–325. doi: 10.1016/j.lungcan.2015.09.018

Table 1.

Patient Characteristics of EGFR, RET and ROS1

All
(n=73)
EGFR
(n=31)
RET
(n=25)
ROS1
(n=17)
p Value
EGFR vs
RET/ROS1
RET vs
ROS1

Age (years),
median
(range)
61 (36, 89) 61 (36, 87) 59 (38, 84) 61 (38, 89) 0.80 0.58
Gender, n(%)
F 49 (67%) 21 (68%) 17 (68%) 11 (65%) 0.99 0.99
M 24 (33%) 10 (32%) 8 (32%) 6 (35%)
Stage, n(%)
1 1 (1%) 0 (0%) 1 (4%) 0 (0%) 0.95 0.90
2 5 (7%) 2 (6%) 2 (8%) 1 (6%) 0.99 (1 vs 2–4) 0.99 (1 vs 2–4)
3 10 (14%) 5 (16%) 2 (8%) 3 (18%)
4 57 (78%) 24 (77%) 20 (80%) 13 (76%)